The price to earnings ratio for GenMark Diagnostics, Inc. (NasdaqGM:GNMK) is -7.194377. This ratio is found by taking the current share price and dividing by earnings per share. Further, Price to Book ratio for GenMark Diagnostics, Inc. NasdaqGM:GNMK is 8.388393. A lower price to book ratio indicates that the stock might be undervalued.

Now we’ll turn to some key quant data and additional ratios. The Current Ratio of GenMark Diagnostics, Inc. (NasdaqGM:GNMK) is 2.04. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company might have trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.

GenMark Diagnostics, Inc. (NasdaqGM:GNMK)’s Leverage Ratio was recently noted as 0.234566. This ratio is calculated by dividing total debt by total assets plus total assets previous year, divided by two. The leverage of a company is relative to the amount of debt on the balance sheet. This ratio is often viewed as one measure of the financial health of a firm.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of GenMark Diagnostics, Inc. (NasdaqGM:GNMK) is 54.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

At the time of writing, GenMark Diagnostics, Inc. (NasdaqGM:GNMK) has a Piotroski F-Score of 3. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

GenMark Diagnostics, Inc. (NasdaqGM:GNMK) has an M-score Beneish of -2.747979. This M-score model is a little known investment tool that was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of GenMark Diagnostics, Inc. (NasdaqGM:GNMK) is 92. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of GenMark Diagnostics, Inc. (NasdaqGM:GNMK) is 91.

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of GenMark Diagnostics, Inc. (NasdaqGM:GNMK) is 16055. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

Shifting gears, we can see that GenMark Diagnostics, Inc. (NasdaqGM:GNMK) has a Q.i. Value of 79.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

At the time of writing, GenMark Diagnostics, Inc. (NasdaqGM:GNMK) has a Piotroski F-Score of 3. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

In conclusion, there are a number of signals that can be looked at in order to determine if a company will continue to grow earnings and if they are a good investment for a portfolio. Potential investors should do all due dilligence before making an investment decision.